Patents
Literature
Patsnap Eureka AI that helps you search prior art, draft patents, and assess FTO risks, powered by patent and scientific literature data.

2 results about "POLYETHYLENE GLYCOL 8" patented technology

Cement grinding aid, its preparation method and application

The application discloses a cement grinding aid, and ingredients are as follows in parts by mass: fly ash 300-500, organic grinding component 15-40, inorganic grinding component 2-8, dehydrating agent 1-3, water absorbing agent 3-6, hydrophobic silicon dioxide 2-5, and double-end silane polyethylene glycol 8-13; the application optimizes component matching, improves the ability of the surface of cement particles to resist moisture in the mixture, effectively accelerates the absorption and volatilization of moisture in the mixture, effectively improves the flowability of cement powder in the mill, and solves the problems of paste ball and mill, reduced yield in the ball milling process of raw materials with high moisture content, and reduced strength in the application process.
Owner:HUAXIN CEMENT CO LTD

Immediate-release, liquid oral pharmaceutical suspension dosage form of eslicarbazepine acetate

PendingUS20260199235A1LicarbazepineBenzoic acid
An immediate-release liquid oral suspension of Eslicarbazepine Acetate, containing between about 5 to about 10 g of active ingredient per 100 mL, along with carbomer homopolymer and microcrystalline cellulose as viscosity modifying agents. It may further comprise, parabens as antimicrobial agent, sucralose as a sweetener, and polyethylene glycol 8 stearate as a surfactant. The suspension is designed to provide bioequivalence to marketed Eslicarbazepine Acetate tablets, ensuring rapid drug release and stability over extended storage periods. The pH is adjusted to 3.0-6.5 to maintain stability, with impurities remaining under 0.05% of the eslicarbazepine content after stress storage conditions. This formulation offers an alternative to solid dosage forms for patients with partial-onset seizures.
Owner:SAPTALIS PHARM LLC